A novel pH-dependent membrane peptide that binds to EphA2 and inhibits cell migration

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Research

Background:

• Aberrant signaling of the EphA2 receptor tyrosine kinase (RTK) and ephrinA1 contributes to cancer metastasis.
• Solid tumors exhibit an acidic extracellular environment, presenting a potential therapeutic target.

Purpose of the Study:

• To design novel pH-dependent molecules for targeted tumor therapy.
• To investigate a new peptide activator for the EphA2 receptor.

Main Methods:

• Engineered a pH-dependent transmembrane peptide (TYPE7) by modifying the EphA2 transmembrane domain.
• Assessed TYPE7's solubility, membrane interaction at different pH levels, and binding to endogenous EphA2.
• Evaluated TYPE7's effect on Akt phosphorylation and cell migration compared to ephrinA1.

Main Results:

• TYPE7 is soluble at neutral pH and inserts into lipid membranes under acidic conditions.
• TYPE7 effectively reduces Akt phosphorylation and cell migration, similar to ephrinA1.
• Significant differences observed in EphA2 clustering and juxtamembrane tyrosine phosphorylation between TYPE7 and ephrinA1 activation.

Conclusions:

• Novel pH-triggered membrane peptides can be designed to activate receptor tyrosine kinases.
• TYPE7 demonstrates potential as a tumor-targeted therapeutic agent by exploiting the acidic tumor microenvironment.
• This study provides new insights into the EphA2 receptor activation mechanism.